Keyphrases
P16 Expression
33%
Soluble Fms-like Tyrosine kinase-1 (sFlt-1)
33%
Cyclin-dependent Kinase 4 (CDK4)
33%
Angiogenic Factors
33%
Inhibitor Resistance
33%
Patients with Breast Cancer
33%
Drug-tolerant Persisters
33%
Pregnant Women
33%
ER+ Breast Cancer
33%
Chemotherapy
33%
Therapy-induced Senescence
33%
Metastatic Triple-negative Breast Cancer
33%
Wee1 Inhibitors
33%
ATR Inhibition
33%
PARP Inhibitor Resistance
33%
Drug-tolerant Persister Cells
25%
ATR Inhibitor
22%
Women with Breast Cancer
16%
Soluble Endoglin
12%
Breast Cancer
12%
Endocrine Therapy
11%
Antitumor Activity
11%
Acquired Resistance
11%
Replication Stress Response
11%
Third Trimester
8%
Taxanes
8%
Clinical Obstetrics
8%
Chemotherapy Cycles
8%
During Pregnancy
8%
Chemotherapy in Pregnancy
8%
Anti-angiogenic State
8%
Selective Intrauterine Growth Restriction (sIUGR)
8%
Preeclampsia
8%
Placental Insufficiency
8%
Obstetric Management
8%
Placental Function
8%
PI3K Inhibitor
7%
Estrogen Receptor-positive Breast Cancer
7%
Patient-derived Xenograft
7%
Breast Cancer Patients
7%
P16INK4a Overexpression
7%
Trastuzumab Duocarmazine
6%
Membrane Permeable
6%
MSK-IMPACT
5%
Reverse Phase Protein Array
5%
Protein Array Analysis
5%
ATM mutation
5%
Xenoimplant
5%
Breast Cancer Drugs
5%
GFRAL
5%
Medicine and Dentistry
Breast Cancer
100%
Biological Marker
36%
CDK4/6 Inhibitor
33%
P16
33%
Angiogenic Factor
33%
Cancer Model
33%
Buparlisib
33%
PARP Inhibitor
33%
Triple Negative Breast Cancer
33%
Diseases
33%
Ovarian Cancer
33%
Antineoplastic Activity
15%
Neoplasm
14%
Endoglin
14%
Hormone Therapy
12%
Overall Survival
11%
Progression Free Survival
11%
Biopsy Technique
11%
Recombination Repair
10%
Homologous Recombination
10%
Pre-Eclampsia
9%
Placental Insufficiency
9%
Obstetrics
9%
Third Trimester Pregnancy
9%
Intrauterine Growth Retardation
9%
Antiangiogenic
9%
Placenta Function
9%
Protein Tyrosine Kinase
9%
Estrogen Receptor Positive Breast Cancer
8%
Xenograft
8%
Antineoplastic Agent
8%
Olaparib
6%
DNA Sequence
5%
Cancer Treatment
5%
Arm
5%
Progressive Disease
5%
Protein Microarray
5%
Anorexia
5%
Adverse Event
5%
Metastatic Breast Cancer
5%
Nausea
5%
Hyperglycemia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
66%
Biological Marker
66%
Triple Negative Breast Cancer
35%
Endocrine Therapy
33%
Antitumor Activity
33%
Growth Differentiation Factor 15
33%
Eribulin
33%
Diseases
33%
Buparlisib
33%
Neoplasm
26%
Estrogen Receptor Positive Breast Cancer
22%
Basal Like Breast Cancer
11%
Alpelisib
11%
Ribociclib
11%
Estrogen Receptor
11%
Antineoplastic Agent
11%
Overall Survival
9%
Progression Free Survival
9%
Malignant Neoplasm
5%
